Aaron Kesselheim of Harvard University tracked sales of Neurontin, a drug approved for epilepsy but prescribed for much more.

ECONOMIST: Johnson & Johnson

In an editorial accompanying the studies, Jerry Avorn and Aaron Kesselheim of Harvard Medical School and Brigham and Women's Hospital, Boston, questioned whether "improper" marketing may have contributed to the off-label use of NovoSeven.

WSJ: Hemophilia Drug's Off-Label Use Is Faulted